JP2013532682A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013532682A5 JP2013532682A5 JP2013521285A JP2013521285A JP2013532682A5 JP 2013532682 A5 JP2013532682 A5 JP 2013532682A5 JP 2013521285 A JP2013521285 A JP 2013521285A JP 2013521285 A JP2013521285 A JP 2013521285A JP 2013532682 A5 JP2013532682 A5 JP 2013532682A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- methyl
- alkyl
- alkenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 17
- 125000003118 aryl group Chemical group 0.000 claims 10
- 125000003342 alkenyl group Chemical group 0.000 claims 8
- 125000000217 alkyl group Chemical group 0.000 claims 8
- 229910052739 hydrogen Inorganic materials 0.000 claims 8
- 239000001257 hydrogen Substances 0.000 claims 8
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 8
- 150000002431 hydrogen Chemical class 0.000 claims 7
- 150000001875 compounds Chemical class 0.000 claims 6
- 125000001072 heteroaryl group Chemical group 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 5
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims 4
- 229910052760 oxygen Inorganic materials 0.000 claims 4
- 229910052717 sulfur Inorganic materials 0.000 claims 4
- VBCIBLUDWOQXTK-UHFFFAOYSA-N 2-[4-[4-[(2,4-dioxo-1,3-thiazolidin-5-yl)methyl]phenoxy]phenyl]acetic acid Chemical compound C1=CC(CC(=O)O)=CC=C1OC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 VBCIBLUDWOQXTK-UHFFFAOYSA-N 0.000 claims 3
- 208000002249 Diabetes Complications Diseases 0.000 claims 3
- 206010012655 Diabetic complications Diseases 0.000 claims 3
- 125000003545 alkoxy group Chemical group 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 208000019423 liver disease Diseases 0.000 claims 3
- LPBFRHDVZVXTSO-VYRBHSGPSA-N (2s)-2-amino-3-[4-[4-[(2,4-dioxo-1,3-thiazolidin-5-yl)methyl]phenoxy]phenyl]propanoic acid Chemical compound C1=CC(C[C@H](N)C(O)=O)=CC=C1OC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 LPBFRHDVZVXTSO-VYRBHSGPSA-N 0.000 claims 2
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 claims 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims 2
- 125000003710 aryl alkyl group Chemical group 0.000 claims 2
- 208000019425 cirrhosis of liver Diseases 0.000 claims 2
- -1 cyano, formyl Chemical group 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 150000002367 halogens Chemical class 0.000 claims 2
- 125000005842 heteroatom Chemical group 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 150000002500 ions Chemical class 0.000 claims 2
- OGXRFCWCSMPYKS-BHWOMJMDSA-N methyl (2s)-2-amino-3-[4-[4-[(2,4-dioxo-1,3-thiazolidin-5-yl)methyl]phenoxy]phenyl]propanoate Chemical compound C1=CC(C[C@H](N)C(=O)OC)=CC=C1OC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 OGXRFCWCSMPYKS-BHWOMJMDSA-N 0.000 claims 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 1
- 102000016912 Aldehyde Reductase Human genes 0.000 claims 1
- 108010053754 Aldehyde reductase Proteins 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 206010007572 Cardiac hypertrophy Diseases 0.000 claims 1
- 208000006029 Cardiomegaly Diseases 0.000 claims 1
- 208000002177 Cataract Diseases 0.000 claims 1
- 206010007749 Cataract diabetic Diseases 0.000 claims 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical class [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- 108090001005 Interleukin-6 Proteins 0.000 claims 1
- 102000004889 Interleukin-6 Human genes 0.000 claims 1
- 208000019693 Lung disease Diseases 0.000 claims 1
- 208000035719 Maculopathy Diseases 0.000 claims 1
- 102000000424 Matrix Metalloproteinase 2 Human genes 0.000 claims 1
- 108010016165 Matrix Metalloproteinase 2 Proteins 0.000 claims 1
- 206010027476 Metastases Diseases 0.000 claims 1
- 102100029438 Nitric oxide synthase, inducible Human genes 0.000 claims 1
- 101710089543 Nitric oxide synthase, inducible Proteins 0.000 claims 1
- 208000018262 Peripheral vascular disease Diseases 0.000 claims 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 208000017442 Retinal disease Diseases 0.000 claims 1
- 206010038923 Retinopathy Diseases 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 1
- 206010047163 Vasospasm Diseases 0.000 claims 1
- 208000026594 alcoholic fatty liver disease Diseases 0.000 claims 1
- 208000008784 apnea Diseases 0.000 claims 1
- 125000004104 aryloxy group Chemical group 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 208000026106 cerebrovascular disease Diseases 0.000 claims 1
- 230000007882 cirrhosis Effects 0.000 claims 1
- 201000007025 diabetic cataract Diseases 0.000 claims 1
- 208000033679 diabetic kidney disease Diseases 0.000 claims 1
- 239000008103 glucose Substances 0.000 claims 1
- 125000001188 haloalkyl group Chemical group 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 208000002780 macular degeneration Diseases 0.000 claims 1
- 159000000003 magnesium salts Chemical class 0.000 claims 1
- 239000002207 metabolite Substances 0.000 claims 1
- 230000009401 metastasis Effects 0.000 claims 1
- 208000031225 myocardial ischemia Diseases 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 230000007823 neuropathy Effects 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 230000000414 obstructive effect Effects 0.000 claims 1
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 201000010065 polycystic ovary syndrome Diseases 0.000 claims 1
- 239000011591 potassium Substances 0.000 claims 1
- 229910052700 potassium Inorganic materials 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
- 229940002612 prodrug Drugs 0.000 claims 1
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 1
- 208000037803 restenosis Diseases 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims 1
- 0 CC(C(*)=O)N(*)* Chemical compound CC(C(*)=O)N(*)* 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN2140CH2010 | 2010-07-28 | ||
| IN2140/CHE/2010 | 2010-07-28 | ||
| IN525/CHE/2011 | 2011-02-23 | ||
| IN525CH2011 | 2011-02-23 | ||
| PCT/IN2011/000210 WO2012014218A1 (en) | 2010-07-28 | 2011-03-28 | Diphenyl ether compounds for the treatment of liver, lung disorders, diabetic complications and cardiovascular diseases |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013532682A JP2013532682A (ja) | 2013-08-19 |
| JP2013532682A5 true JP2013532682A5 (cg-RX-API-DMAC7.html) | 2014-05-15 |
| JP5957452B2 JP5957452B2 (ja) | 2016-07-27 |
Family
ID=44247871
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013521285A Expired - Fee Related JP5957452B2 (ja) | 2010-07-28 | 2011-03-28 | 肝臓、肺の障害、糖尿病合併症および心血管疾患の処置のためのジフェニルエーテル化合物 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20140187594A1 (cg-RX-API-DMAC7.html) |
| EP (2) | EP2987488A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP5957452B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN103108634B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2011284256B8 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2805245A1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2565487T3 (cg-RX-API-DMAC7.html) |
| HU (1) | HUE028725T2 (cg-RX-API-DMAC7.html) |
| PL (1) | PL2598142T3 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2012014218A1 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA201300822B (cg-RX-API-DMAC7.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20170105996A1 (en) | 2015-10-16 | 2017-04-20 | Teva Pharmaceutical Industries, Ltd. | Treatment of non-alcoholic fatty liver disease or non-alcoholic steatohepatitis with delayed-release 6-mercaptopurine |
| WO2018204775A1 (en) | 2017-05-05 | 2018-11-08 | Hepanova, Inc. | Amino-aryl-benzamide compounds and methods of use thereof |
| CN113750089B (zh) * | 2021-10-13 | 2023-09-19 | 南方医科大学南方医院 | 2-芳基-1,3二氢苯并咪唑衍生物在制备治疗慢性肝病的药物中的用途 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH08109175A (ja) * | 1994-10-07 | 1996-04-30 | Torii Yakuhin Kk | チアゾリジン−２−オンエステル誘導体 |
| US7781464B2 (en) | 2003-01-17 | 2010-08-24 | Bexel Pharmaceuticals, Inc. | Heterocyclic diphenyl ethers |
| US6794401B2 (en) | 2003-01-17 | 2004-09-21 | Bexel Pharmaceuticals, Inc. | Amino acid phenoxy ethers |
| US7521465B2 (en) * | 2003-01-17 | 2009-04-21 | Bexel Pharmaceuticals, Inc. | Diphenyl ether derivatives |
| US7087576B2 (en) * | 2003-10-07 | 2006-08-08 | Bexel Pharmaceuticals, Inc. | Dipeptide phenyl ethers |
| KR20080025662A (ko) * | 2005-03-18 | 2008-03-21 | 오키드 케미칼즈 앤드 파마수티컬즈 리미티드 | 신규 티로신 유도체 |
| WO2006138475A2 (en) * | 2005-06-16 | 2006-12-28 | Jenrin Discovery | Mao-b inhibitors useful for treating obesity |
| PT2144604E (pt) * | 2007-02-28 | 2011-10-19 | Conatus Pharmaceuticals Inc | Métodos para o tratamento da hepatite c viral crónica utilizando ro-113-0830 |
| WO2008109727A1 (en) * | 2007-03-07 | 2008-09-12 | Janssen Pharmaceutica N.V. | Substituted phenoxy thiazolidinediones as estrogen related receptor-alpha modulators |
| WO2009030968A1 (en) * | 2007-09-05 | 2009-03-12 | Orchid Research Laboratories Limited | Mao a inhibitors with a diphenyl ether-substructure. |
| JP5583022B2 (ja) * | 2007-11-30 | 2014-09-03 | ザ レジェンツ オブ ザ ユニヴァースティ オブ カリフォルニア | システアミン生成物を用いる非アルコール性脂肪性肝炎（ｎａｓｈ）の治療方法 |
-
2011
- 2011-03-28 ES ES11720594.8T patent/ES2565487T3/es active Active
- 2011-03-28 US US13/809,604 patent/US20140187594A1/en not_active Abandoned
- 2011-03-28 EP EP15189194.2A patent/EP2987488A1/en not_active Withdrawn
- 2011-03-28 AU AU2011284256A patent/AU2011284256B8/en not_active Ceased
- 2011-03-28 HU HUE11720594A patent/HUE028725T2/en unknown
- 2011-03-28 WO PCT/IN2011/000210 patent/WO2012014218A1/en not_active Ceased
- 2011-03-28 EP EP11720594.8A patent/EP2598142B1/en not_active Not-in-force
- 2011-03-28 CN CN201180037004.1A patent/CN103108634B/zh not_active Expired - Fee Related
- 2011-03-28 PL PL11720594T patent/PL2598142T3/pl unknown
- 2011-03-28 JP JP2013521285A patent/JP5957452B2/ja not_active Expired - Fee Related
- 2011-03-28 CA CA2805245A patent/CA2805245A1/en not_active Abandoned
-
2013
- 2013-01-31 ZA ZA2013/00822A patent/ZA201300822B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011509916A5 (cg-RX-API-DMAC7.html) | ||
| US20110212975A1 (en) | Antiviral compounds and methods of making and using thereof | |
| JP2017518959A5 (cg-RX-API-DMAC7.html) | ||
| US20040152744A1 (en) | Activator for peroxisome proliferator- activated receptor | |
| JP2014523901A5 (cg-RX-API-DMAC7.html) | ||
| JP2009527501A5 (cg-RX-API-DMAC7.html) | ||
| JP2013526494A5 (cg-RX-API-DMAC7.html) | ||
| US11040963B2 (en) | Piperazine derivatives for influenza virus inhibitions | |
| JP2020073466A (ja) | プロドラッグ化合物およびそれらの使用 | |
| JP2014037426A5 (cg-RX-API-DMAC7.html) | ||
| JP2013526520A5 (cg-RX-API-DMAC7.html) | ||
| CA2770140A1 (en) | Antiviral compounds and methods of making and using thereof cross reference to related applications | |
| JP2015521167A5 (cg-RX-API-DMAC7.html) | ||
| IL287159B1 (en) | Small molecules agonists for FXR (farnesoid X receptor) and method for their preparation and use | |
| JP2009528997A5 (cg-RX-API-DMAC7.html) | ||
| WO2009012650A1 (en) | Aryl pyrimidine derivatives, preparation methods and pharmaceutical uses thereof | |
| RU2017121460A (ru) | Производные пиридинкарбоксамида, способ их получения и их фармацевтическое применение | |
| JP2010535155A (ja) | ウイルスポリメラーゼ阻害剤 | |
| JPWO2006059744A1 (ja) | ペルオキシソーム増殖剤活性化受容体δの活性化剤 | |
| CN110214133A (zh) | N-{[2-(哌啶-1-基)苯基](苯基)甲基}-2-(3-氧代-3,4-二氢-2H-1,4-苯并噁嗪-7-基)乙酰胺衍生物及相关化合物作为RORγ调节剂用于治疗自体免疫疾病 | |
| JP2013532682A5 (cg-RX-API-DMAC7.html) | ||
| KR20070045272A (ko) | 2-페닐피리딘 유도체 | |
| US10196411B2 (en) | Tizoxanide phosphate and alkane sulfonate and pharmaceutical applications thereof | |
| JP2010535156A (ja) | ウイルスポリメラーゼ阻害剤 | |
| WO2018141854A1 (en) | Piperazine derivatives for influenza virus inhibition |